Globus Medical (NYSE:GMED) Stock Rating Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Globus Medical from Buy to Hold. Analyst views remain mixed: MarketBeat’s consensus is Moderate Buy with a $96.92 average price target, while BMO also cut its rating and target.
• Globus Medical’s quarterly EPS of $1.23 beat the $1.20 estimate, but revenue of $763.7 million fell short of expectations and declined 0.7% year over year.
• Outlook remains a concern: 2026 revenue guidance is below consensus, with management citing product-launch delays and weak Nevro sales. The company also increased its share-repurchase authorization by $500 million.

Globus Medical (NYSE:GMED - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other brokerages have also weighed in on GMED. Canaccord Genuity Group cut their price objective on shares of Globus Medical from $115.00 to $105.00 and set a "buy" rating on the stock in a report on Friday. BMO Capital Markets downgraded Globus Medical from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $94.00 to $78.00 in a report on Friday. Weiss Ratings reiterated a "hold (c+)" rating on shares of Globus Medical in a research note on Friday, October 9th. Needham & Company LLC lowered their target price on Globus Medical from $117.00 to $100.00 and set a "buy" rating on the stock in a research note on Friday. Finally, UBS Group started coverage on Globus Medical in a report on Tuesday, July 28th. They set a "neutral" rating and a $82.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $96.92.

Globus Medical Stock Performance

NYSE GMED opened at $70.67 on Friday. The company's 50 day moving average price is $77.20 and its 200 day moving average price is $83.18. The firm has a market capitalization of $9.49 billion, a price-to-earnings ratio of 16.15, a PEG ratio of 1.28 and a beta of 0.98. Globus Medical has a one year low of $70.39 and a one year high of $101.40.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.03. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The company had revenue of $763.72 million during the quarter, compared to analysts' expectations of $792.39 million. During the same period last year, the business earned $1.18 EPS. The business's quarterly revenue was down .7% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Sell-side analysts forecast that Globus Medical will post 4.99 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Stephen Zarrilli sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James R. Tobin sold 30,000 shares of the company's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the sale, the director directly owned 15,000 shares of the company's stock, valued at approximately $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 60,000 shares of company stock valued at $4,838,400 in the last ninety days. Corporate insiders own 18.38% of the company's stock.

Institutional Trading of Globus Medical

Hedge funds have recently made changes to their positions in the company. William Blair Investment Management LLC raised its holdings in Globus Medical by 12.6% in the 3rd quarter. William Blair Investment Management LLC now owns 1,447,365 shares of the medical device company's stock valued at $108,408,000 after acquiring an additional 162,469 shares during the last quarter. Allworth Financial LP boosted its position in shares of Globus Medical by 3.5% during the 3rd quarter. Allworth Financial LP now owns 12,797 shares of the medical device company's stock valued at $1,011,000 after purchasing an additional 436 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Globus Medical by 335.0% during the third quarter. Russell Investments Group Ltd. now owns 143,614 shares of the medical device company's stock worth $10,758,000 after acquiring an additional 110,602 shares in the last quarter. Maryland State Retirement & Pension System increased its stake in shares of Globus Medical by 14.7% during the third quarter. Maryland State Retirement & Pension System now owns 6,743 shares of the medical device company's stock valued at $505,000 after purchasing an additional 863 shares in the last quarter. Finally, Jacobi Capital Management LLC purchased a new stake in Globus Medical during the third quarter valued at $40,000. Hedge funds and other institutional investors own 95.16% of the company's stock.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.